Top Markets
Coin of the day
Alpine Immune Sciences, Inc. Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc.

ALPN
Classifica tra le azioni #6581
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company... Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and advancing protein-based immunotherapies. Their therapeutic endeavors address a range of conditions, including various cancers, autoimmune and inflammatory disorders, among others. The company's pipeline features ALPN-101, an ICOS/CD28 antagonist program being developed for autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor aimed at treating cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated inflammatory and autoimmune conditions. Alpine Immune Sciences has established strategic collaborations, including an agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101, and a partnership with Adaptimmune Therapeutics plc to create next-generation SPEAR T cell products. The company was founded in 2007 and operates from its headquarters in Seattle, Washington.
Prezzo delle azioni
$64.97
Ultima sincronizzazione: 2024-05-20
Capitalizzazione di mercato
$1.97B
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
US
Scambia Alpine Immune Sciences, Inc. (ALPN)

Categoria

Storico del prezzo dell'azione per Alpine Immune Sciences, Inc. (ALPN)
Prezzo di chiusura più alto: $64.81 il 2024-05-01

Prezzo di chiusura più basso: $59.56 il 2015-06-01
Storico del prezzo dell'azione di Alpine Immune Sciences, Inc. dal 2015 al 2026
Andamento annuale del prezzo dell'azione
Anno Performance
2024 256.53%
2023 178.29%
2022 -49.70%
2021 1.90%
2020 264.34%
2019 -23.56%
2018 -58.58%
2017 29.87%
2016 -73.99%
2015 0.00%
Prezzo dell'azione per aziende simili o concorrenti
Azienda Prezzo dell'azione Variazione 1a% Il paese
$548.36 40.94%
US
$1.06K 49.46%
NL
$122.63 -12.65%
AU
$140.81 461.00%
US
$765.25 7.19%
CH